Startup profile · funding coverage
Octant Bio
Synthetic-biology drug discovery using engineered human cell lines as disease reporters.
Stage
series b
Status
private
Coverage
full
Why Octant Bio is interesting
Sri Kosuri's antedisciplinary biotech — a16z led the Series A (2020) for GPCR drug maps built from programmable cell reporters; raised $115M+ total.
Key facts
- Series A (May 2020): $30M led by a16z; 8VC participated (GenomeWeb, a16z)
- Series B (Apr 2022): additional financing; total raised ~$115M (Tracxn)
- Co-investors not in VCT directory: 8VC, Catalio Capital, SV Angel
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
Investors in our directory
Funds linked from Octant Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Octant Bio's financing or category context.
Last updated: 2026-07-24